MuPrime™ Tumor Homografts

Immunocompetent models carrying clinically-relevant oncogenic mutations

MuPrime models are homografts of spontaneous or carcinogen induced GEMM tumors grafted in immunocompetent syngeneic hosts. Developed from virtually any GEMM, tumor homografts are broadening the number and molecular pathology of syngeneic models for preclinical I/O research.

MuPrime tumor homografts are never passaged in vitro or ex vivo. As a result, the original tumor histopathology, molecular pathology, and key oncogenic driver mutations are preserved.

The MuPrime platform offers:
- Unique models, encompassing disease-specific mutations relevant to human cancers.
- The predictive power of GEMM combined with operational simplicity required for in vivo pharmacology studies.
- A fully competent mouse immune system.
- Well-characterized models with histopathology, immune checkpoint and SoC benchmarking, and immune profiling data available via our online database MuBase®.
- Scalability that enables large-scale screening.

<table>
<thead>
<tr>
<th>Patient PDAC</th>
<th>Mouse PDAC from KPC GEMM</th>
<th>Subcutaneous homograft tumor</th>
<th>Orthotopic homograft tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Image of tissue</td>
<td>Image of tissue</td>
<td>Image of tissue</td>
<td>Image of tissue</td>
</tr>
</tbody>
</table>

Kras (G12D)/Trp53 null/Pdx1-cre (KPC) tumor homograft model for the evaluation of novel pancreatic ductal adenocarcinoma (PDAC) treatments

**Survival (%)**

**Treatment Days**

- Vehicle 0mg/kg q.d., p.o.
- Treatment 1
- Treatment 2
- Treatment 3

Explore Scientific Data
Log into MuBase to review murine I/O model data.
mubase.crownbio.com

Schedule Scientific Consultation
Request a consultation to discuss your project.
consultation@crownbio.com

Contact Sales
US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com

A JSR Life Sciences Company
+1.855.827.6968 | busdev@crownbio.com | www.crownbio.com